Substack · Pierce Capital Research · Steve Wagner
Discounted Assets, Premium Potential: The Case for Coherus Oncology
Taking a Look at Coherus Oncology (CHRS), Special Situation Arbitrage Idea.
Since publication +18.3% α −9.6 pp vs S&P 500 · USD
US · 2 entries · 1 publication
CHRS
Coherus Oncology, Inc.
- Entries
- 2
- Bullish
- 0
- Bearish
- 0
- First
- May 13, 2025
- Latest
- Jun 9, 2025
No entry states a stance.
Jan 25 – Oct 26 · per month
Full performance tracking Pro · free during launch
Alpha of every thesis on CHRS at 1, 3 and 6 months and since publication, and the full chart vs its benchmark.Free during launch: log in or sign up with your email to see it.
Sign up freeTimeline
Newest to oldest- June 2025 1 entry
- May 2025 1 entry
Substack · Pierce Capital Research · Steve Wagner
Coherus BioSciences Q1 2025 Earnings: Transition Complete, But the Proof Still Awaits
Taking a Look at Coherus BioSciences (CHRS) Earnings Results.
Since publication +22.4% α −8.0 pp vs S&P 500 · USD
Prices as of the Oct 27, 2026 close. Past performance does not guarantee future results. Price-only, excluding dividends, in local currency. Data may be delayed or inaccurate. Not investment advice. How it is calculated.